| Patents for A61P 35 - Antineoplastic agents (221,099) |
|---|
| 03/03/2011 | CA2808277A1 Novel colchicine derivatives, methods and uses thereof |
| 03/03/2011 | CA2793090A1 Sphingosine type 1 inhibitors and methods for making and using same |
| 03/03/2011 | CA2772575A1 Raf inhibitor compounds and methods of use thereof |
| 03/03/2011 | CA2772572A1 Bispecific immunocytokine dock-and-lock (dnl) complexes and therapeutic use thereof |
| 03/03/2011 | CA2772551A1 Cytotoxic t-lymphocyte-inducing immunogens for prevention, treatment, and diagnosis of cancer |
| 03/03/2011 | CA2772489A1 Isotopically labeled neurochemical agents and uses thereof for diagnosing conditions and disorders |
| 03/03/2011 | CA2772316A1 1h-pyrazolo [3,4-b] pyridine compounds for inhibiting raf kinase |
| 03/03/2011 | CA2772301A1 Combination therapy with nanoparticle compositions of taxane and hedgehog inhibitors |
| 03/03/2011 | CA2772102A1 Conjugates of pyrrolo[1,4] benzodiazepine dimers as anticancer agents |
| 03/03/2011 | CA2772093A1 Np-1 antagonists and their therapeutic use |
| 03/03/2011 | CA2772074A1 Raf inhibitor compounds and methods of use thereof |
| 03/03/2011 | CA2772071A1 Raf inhibitor compounds and methods of use thereof |
| 03/03/2011 | CA2772036A1 Targeting pax2 for the treatment of breast cancer |
| 03/03/2011 | CA2771992A1 Kinase inhibitors |
| 03/03/2011 | CA2771933A1 Bisphosphonates as inhibitors of acid sphingomyelinase |
| 03/03/2011 | CA2771895A1 Raf inhibitor compounds and methods of use thereof |
| 03/03/2011 | CA2771893A1 Raf inhibitor compounds and methods of use thereof |
| 03/03/2011 | CA2771890A1 Condensed quinolines as protein kinase modulators |
| 03/03/2011 | CA2771833A1 Fused heterocyclic ring derivative and use thereof |
| 03/03/2011 | CA2771789A1 Combination therapy for treating proliferative diseases |
| 03/03/2011 | CA2771775A1 Compounds and compositions as protein kinase inhibitors |
| 03/03/2011 | CA2771673A1 Compounds and compositions as protein kinase inhibitors |
| 03/03/2011 | CA2770161A1 Humanized anti-cdcp1 antibodies |
| 03/03/2011 | CA2770141A1 Antibodies against cdcp1 for the treatment of cancer |
| 03/03/2011 | CA2769289A1 Development of universal cancer drugs and vaccines |
| 03/02/2011 | EP2290063A1 Sirna of human osteopontin |
| 03/02/2011 | EP2289946A1 A polyglycol modified chitosan oligosaccharide fatty acid graft, preparation method thereof and use of the same |
| 03/02/2011 | EP2289942A2 Anti-HER2 antibody variants |
| 03/02/2011 | EP2289940A2 Treatment of metastatic disease |
| 03/02/2011 | EP2289910A2 Differential in tumour gene products and use of same |
| 03/02/2011 | EP2289900A1 Bisphosphonates as inhibitors of acid sphingomyelinase |
| 03/02/2011 | EP2289892A1 Maleimide derivatives, pharmaceutical compositions amd methods for treatment of cancer |
| 03/02/2011 | EP2289883A1 Novel FXR (NR1H4) binding and activity modulating compounds |
| 03/02/2011 | EP2289876A1 Bis(thio-hydrazide amide) compounds in combination with taxol for treating cancer |
| 03/02/2011 | EP2289559A1 Anit-CD70 antibody-drug conjugates and their use for the treatment of cancer and immune disorders |
| 03/02/2011 | EP2289558A1 Bisphosphonate-prodrugs |
| 03/02/2011 | EP2289551A1 Immunotherapy of autoimmune disorders using antibodies which target B-cells |
| 03/02/2011 | EP2289549A2 Immunoconjugates for treating cancer |
| 03/02/2011 | EP2289543A1 Treatment of hematologic malignancies associated with circulating tumor cells using chimeric anti-cd20 antibody |
| 03/02/2011 | EP2289530A1 Use of an extract obtained from plants of the sub-family Rutoideae in the treatment of cancer |
| 03/02/2011 | EP2289525A1 Use of IL-21 for expanding lymphoid cells and for anticancer adoptive immunotherapy |
| 03/02/2011 | EP2289521A2 Compositions and methods for use in tergeting vascular destruction |
| 03/02/2011 | EP2289516A1 Methods and means for the treatment of HPV induced intraepithelial neoplasias |
| 03/02/2011 | EP2289515A2 Combinations comprising a diaryl urea and an interferon |
| 03/02/2011 | EP2289508A1 Combined treatment for lung cancer |
| 03/02/2011 | EP2289504A2 SIRT1 modulators for manipulating cell/organism lifespan/stress response |
| 03/02/2011 | EP2289503A2 Treating muscle wasting with selective androgen receptor modulators |
| 03/02/2011 | EP2289498A1 Use of inhibitors of glutaminyl clyclase |
| 03/02/2011 | EP2288717A1 Monoclonal antibodies to basic fibroblast growth factor |
| 03/02/2011 | EP2288704A2 Enhancement of drug therapy by mirna |
| 03/02/2011 | EP2288702A1 Combination therapies against cancer |
| 03/02/2011 | EP2288611A1 Aurora kinase modulators and method of use |
| 03/02/2011 | EP2288610A1 Azetidine and cyclobutane derivatives as jak inhibitors |
| 03/02/2011 | EP2288602A1 Tricyclic 2,4-diamin0-l,3,5-triazine derivatives useful for the treatment of cancer and myeloproliferative disorders |
| 03/02/2011 | EP2288406A2 A magnetic breather pump and a method for treating a brain tumor using the same |
| 03/02/2011 | EP2288388A1 Achievement of high therapeutic index through molecular imaging guided targeted drug treatment |
| 03/02/2011 | EP2288383A1 Combinations vegf(r) inhibitors and hepatocyte growth factor (c-met) inhibitors for the treatment of cancer |
| 03/02/2011 | EP2288379A2 Dual delivery system for heterologous antigens |
| 03/02/2011 | EP2288363A1 Plant extract and its therapeutic use |
| 03/02/2011 | EP2288351A2 Novel pyrrolidone derivatives for use as metap-2 inhibitors |
| 03/02/2011 | EP2288261A2 Polymeric systems containing intracellular releasable disulfide linker for the delivery of oligonucleotides |
| 03/02/2011 | EP2288258A1 Inhibition of neovascularization by cerium oxide nanoparticles |
| 03/02/2011 | EP2190834B1 Pyridoneamide derivatives as focal adhesion kinase (fak) inhibitors and their use for the treatment of cancer |
| 03/02/2011 | EP2040712B1 Carbonate and carbamate prodrugs of thiazolo [4,5-d] pyrimidines |
| 03/02/2011 | EP1981862B1 Lanthionine-related compounds for the treatment of inflammatory diseases |
| 03/02/2011 | EP1833850B1 Framework residue substituted humanized col-1 antibodies and their use |
| 03/02/2011 | EP1830827B1 Perfluorocarbon liquids to remove carcinogens |
| 03/02/2011 | EP1704148B1 Novel fused pyrrolocarbazoles |
| 03/02/2011 | EP1663320B1 Targeting of tumor vasculature using radiolabelled antibody l19 against fibronectin ed-b |
| 03/02/2011 | EP1646656B1 Human antibody molecules for il-13 |
| 03/02/2011 | EP1638552B1 Use of (3.2.0) heterocyclic compounds and analogs thereof for the treatment of cancer |
| 03/02/2011 | EP1436403B1 Use of the adenoviral e2 late promoter |
| 03/02/2011 | EP1001945B1 QUINOLINE AND QUINOXALINE COMPOUNDS WHICH INHIBIT PLATELET-DERIVED GROWTH FACTOR AND/OR p56lck TYROSINE KINASES |
| 03/02/2011 | CN1714150B Genetic products differentially expressed in tumors and the use thereof |
| 03/02/2011 | CN1674935B Biofunctional composition containing CpG or oligo-/polynucleotide and toxin or enterotoxin |
| 03/02/2011 | CN101983207A Anti mif antibodies |
| 03/02/2011 | CN101983191A Oxim derivatives as hsp90 inhibitors |
| 03/02/2011 | CN101983071A Use of a type ii anti-cd20 antibody with increased antibody dependent cellular cytotoxicity (adcc) in combination with cyclophosphamide, vincristine and doxorubicine for treating non-hodgkin' s lymphomas |
| 03/02/2011 | CN101983057A Method for treating fibrosis and cancer with imidazolium and imidazolinium compounds |
| 03/02/2011 | CN101982464A Annonaceous acetogenin compound and synthesis method and application thereof |
| 03/02/2011 | CN101982458A 3-amino-3-arylpropionic acid and preparation method thereof |
| 03/02/2011 | CN101982196A Traditional Chinese medicine composition for treating lung cancer, preparation method and application thereof |
| 03/02/2011 | CN101982184A Preparation method of taraxacum extract |
| 03/02/2011 | CN101982177A Flexible nano realgar liposome as well as preparation method and application thereof |
| 03/02/2011 | CN101982171A Application of fenugreek biflavone glycosides for preparing anti-virus or/and anti-tumor drugs |
| 03/02/2011 | CN101982168A Quercetin nano-micelle preparation and preparation method thereof |
| 03/02/2011 | CN101543488B A medicine containing caffeic acid 3,4-dihydroxyl phenethyl ester and its uses |
| 03/02/2011 | CN101538272B Phenyl propanoid derivative, preparation method thereof and application thereof to preparation of medicines resisting breast cancer |
| 03/02/2011 | CN101185649B Levoleucovorin freeze-dried injection agent and preparation method and pharmaceutical use thereof |
| 03/02/2011 | CN101020637B Preparation process and application of resemary acid |
| 03/01/2011 | US7897842 GnTIII expression in plants |
| 03/01/2011 | US7897757 for treating, preventing, inhibiting, or reducing obesity, insulin resistance, diabetes and any other disease, trait, or condition that is related to or will respond to the levels of PTP-1B in a cell or tissue |
| 03/01/2011 | US7897740 Secreted protein called 36P6D5 characteristic of tumors |
| 03/01/2011 | US7897729 Polymeric immunoglobulin fusion proteins that target low affinity FcγReceptors |
| 03/01/2011 | US7897640 Bactericide, viricide, antitumor agents; anticancer agents |
| 03/01/2011 | US7897618 N-aroyl cyclic amine derivatives as orexin receptor antagonists |
| 03/01/2011 | US7897605 Pyrimidine compounds |
| 03/01/2011 | US7897590 Methods to mobilize progenitor/stem cells |
| 03/01/2011 | US7897584 Taxanes covalently bounded to hyaluronic acid or hyaluronic acid derivatives |
| 03/01/2011 | US7897562 Apoptosis-inducing agent and method for inducing apoptosis |